SNX-482 vs Didemnin B
Head-to-head comparison of SNX-482 (SNX-482 peptide from Hysterocrates gigas venom) and Didemnin B (Didemnin B) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | SNX-482 | Didemnin B |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | SNX-482 peptide from Hysterocrates gigas venom | Didemnin B |
| Molecular Weight | 4,300 Da | 1112.4 Da |
| Half-Life | Minutes to hours | N/A |
| Amino Acids | 41 | N/A |
| Typical Dose | 0.01-1 nmol intrathecal|1-100 nM in vitro|single-dose electrophysiology studies | 0.05-2 mg/m2 IV in early trials |
| Route | Intrathecal | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 120 |
| Research Status | Pre-clinical | Clinical |
SNX-482 Benefits
- ✓Cav2.3 blockade
- ✓synaptic transmission studies
- ✓excitability mapping
- ✓pain and epilepsy research
Didemnin B Benefits
- ✓antineoplastic
- ✓antiviral
- ✓pro-apoptotic
- ✓immunomodulatory
SNX-482 Dosing
Patch-clamp Cav2.3 assays|Intrathecal neurophysiology studies|Acute channel-blockade experiments
Didemnin B Dosing
historic IV phase I/II oncology regimens|dose escalation in early trials|no approved dosing regimen
SNX-482 Side Effects
- ⚠Ataxia at high exposure
- ⚠off-target calcium-channel block
- ⚠cardiovascular effects in animal models
Didemnin B Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠myelosuppression
Research Overview
SNX-482
SNX-482 has been used to dissect R-type calcium currents in neurons and endocrine cells, and to map the role of Cav2.3 in excitability. Its selectivity profile has made it a standard research reagent in channel pharmacology.
Didemnin B
Didemnin B showed strong cytotoxic and antiviral activity in early literature and became an important scaffold for later marine drug development. Its clinical progress was limited by toxicity, but it remains highly cited as a foundational marine depsipeptide.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.